All In Biotech

Drug Trial Radar · NCT03201796

Prulifloxacin in Chronic Bacterial Prostatitis (CBP)

Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis.

Last checked: Nov 21, 2026Latest source record: May 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Feb 2, 2016

Primary completion

May 19, 2020

Study completion May 19, 2020

Sponsor

Sponsor type
Industry
Collaborators
Hippocrates Research
First posted
Jun 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the efficacy and safety of prulifloxacin in comparison to levofloxacin in the treatment of patients affected by CBP.

Conditions

  • Chronic Bacterial Prostatitis

Interventions

  • Prulifloxacin 600 mgDrug

    Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.

  • Levofloxacin 500mgDrug

    Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication of bacterial growthTime frame: 7 days after the EOT

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Urology Clinic General Hospital of Athens "GENNIMATAS"

    Athens, Greece

  • Urology Department General Hospital of Piraeus "TZANEIO"

    Piraeus, Greece

  • U.O. di Urologia- Azienda Ospedaliera San Giuseppe Moscati

    Avellino, Italy

  • U.O. Dipartimento della Donna, del bambino e delle malattie urologiche - Azienda ospedaliero- Universitaria e Policlinico di Bologna

    Bologna, Italy

  • Urologia- Azienda Ospedaliero - Universitaria "Policlinico - Vittorio Emanuele"

    Catania, Italy

  • Clinica Urologica- Azienda Ospedaliero Universitaria Mater Domini

    Catanzaro, Italy

  • Azienda Ospedaliero-Universitaria "Careggi"

    Florence, Italy

  • Azienda Ospedaliera Universitaria "Federico II"- Dip. Di Ostreticia, ginecologia, Urologia

    Naples, Italy

  • Clinica Urologica del Dipartimento di Scienze Chirurgiche- Policlinico Universitario Agostino Gemelli di Roma

    Roma, Italy

  • S.C. Urologia- AO "Città della Salute e della Scienza" di Torino - OSP.S. GIOV.BATTISTA MOLINETTE

    Torino, Italy

  • Urologia- Ospedale di Trento- Presidio ospedaliero S. Chiara - Azienda Provinciale per i servizi sanitari (APSS)

    Trento, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.